Announcement on the U.S. distribution partnership and launch timing for Bondlido. Discussions with Terrain Pharmaceuticals are ongoing, with a U.S. distribution license agreement expected to be signed within 2026. The initial shipment is scheduled for delivery in November 2026. Revenue recognition will depend on contract terms; at this time the impact on the fiscal year ending December 2026 earnings guidance is undetermined.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4576","jir_company_name":"D. Western Therapeutics Institute, Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4576-20261030-01.pdf","jir_short_summary":"Announcement on the U.S. distribution partnership and launch timing for Bondlido. Discussions with Terrain Pharmaceuticals are ongoing, with a U.S. distribution license agreement expected to be signed within 2026. The initial shipment is scheduled for delivery in November 2026. Revenue recognition will depend on contract terms; at this time the impact on the fiscal year ending December 2026 earnings guidance is undetermined.","jir_summary":"### Key Points on Partnership and Launch Timing\nA distribution partnership with Terrain Pharmaceuticals for Bondlido's U.S. market rollout is progressing, with the agreement expected to be finalized within 2026. The initial shipment is scheduled to be delivered to Terrain in November. Finalization of contract terms will take additional time, and reviews of distribution channels and supply plans are ongoing.\n\n### Financial Impact and Outlook\nRevenue from this product under this arrangement will depend on the finalized contract terms, and may result in revenue-sharing receipts; however, the impact on the fiscal year ending December 2026 earnings guidance is currently undetermined. The company will disclose any material impact promptly once confirmed.","jir_financial_highlights":"Unknown: Unknown (Unknown)\nTiming of Bondlido distribution license agreement signing: within 2026 (Unknown)\nInitial shipment delivery timing: November 2026 (Unknown)","jir_category":"","jir_hashtags":"#BondlidoPartnership, #USMarketStrategy","jir_key_figures":"Timing of Bondlido distribution license agreement signing: within 2026\nInitial shipment delivery timing: November 2026\nImpact on fiscal year ending December 2026 earnings guidance: Undetermined","jir_meta_title":"D. Western Therapeutics Institute, Inc. Announces U.S. Distribution Partnership and Launch Timing for Bondlido\uff5c2026","jir_meta_description":"Announcement on Bondlido's U.S. distribution partnership and launch timing. Basic terms are under discussion with Terrain Pharmaceuticals, with an agreement expected within 2026. Initial shipment is scheduled for delivery in November; impact on the fiscal year ending December 2026 earnings is undetermined.","jir_og_title":"Announcement of U.S. Distribution Partnership and Launch Timing for Bondlido\uff5cD. Western Therapeutics Institute IR","jir_og_description":"Distribution partnership and launch timing for Bondlido in the U.S. Initial shipment scheduled for November, agreement expected within 2026. Impact on earnings is undetermined.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59943,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-138899","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n